Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02133924|
Recruitment Status : Recruiting
First Posted : May 8, 2014
Last Update Posted : February 6, 2018
This research trial is designed to study the safety and effectiveness of combining the study drug, Natalizumab (Tysabri®) with the standard treatment, the use of steroids, as a new treatment for acute graft versus host disease (acute GVHD). GVHD is the most common serious complication, after bone marrow transplant. GVHD occurs when the donor cells (the graft), treat the recipient's body as "foreign" and attack the cells in the recipient's body. During this immune system response, donor cells damage body tissues, such as the skin, liver, stomach, and/or intestines. Acute GVHD can be severe and if severe, potentially fatal to the transplant recipient. Acute GVHD usually happens within the first several months after transplant.
The goal of this research is to develop a safer and more effective treatment for acute GVHD, and particularly for acute GVHD that affects the gastrointestinal (or GI) tract, with the ultimate goal being safer and more effective transplant therapies for blood cancers such as leukemia, lymphoma, and multiple myeloma.
|Condition or disease||Intervention/treatment||Phase|
|Acute Graft Versus Host Disease||Drug: natalizumab Drug: steroids||Phase 2|
The only proven effective treatment for patients with acute graft vs host disease is steroids. Patients not responding to steroid treatment are at high risk for death. Unfortunately, based on the early symptoms, it is not possible to tell whether a patient will respond to steroids, when GVHD is diagnosed and treatment with steroids, such as prednisone, is started.
This research trial is designed to study the safety and effectiveness of combining the study drug, Natalizumab (Tysabri®) with the use of steroids to treat acute GVHD in patients at the earliest stages of clinical symptoms, but, by using a proprietary method developed at the University of Michigan and the Icahn School of Medicine at Mount Sinai, are predicted to be at high risk for not responding to steroid therapy, the standard of care.
Investigators at Mount Sinai have developed a research method believed that it might make it possible to predict who is at high risk for not responding to steroids. This method, called Ann Arbor GVHD scoring, uses the levels of naturally occurring chemicals in the blood (called biomarkers) to determine a patient's GVHD score(1, 2, or 3).
A hypothesis is that most patients with Ann Arbor score 3 GVHD, will not respond well to steroid treatment. The investigators research shows that almost half of the patients with Ann Arbor grade 3 GVHD, will die within 6 months of their GVHD diagnosis. Most of the deaths are due to intestinal GVHD, which sometimes does not develop, until after standard steroid treatment has already begun.
Only patients with Ann Arbor score 3 GVHD, will be eligible for this study treatment. It is important to understand that Ann Arbor GVHD grading is not approved for clinical use. It can only be used as a test for research purposes. In this study, patients must have their blood tested to determine, if they qualify as Ann Arbor score 3 GVHD, and must start the study treatment within 3 days of starting systemic steroid treatment for acute GVHD.
The study will test whether the investigators can improve steroid response and prevent death from GVHD with the combination therapy, by blocking the donor cells from getting to the intestine and causing damage. Natalizumab (Tysabri®) is a drug that works by blocking the signals that cause immune cells like donor cells, to travel to organs like the intestine or brain.
Natalizumab is FDA-approved in adults, to treat Crohn's disease, a chronic condition where immune cells cause damage to the digestive system (such as the stomach, intestines). It is also used to treat multiple sclerosis where immune cells cause damage to the nervous system in the brain. Its intended use is for patients with disease that has not responded to the standard treatment, or cannot tolerate the side effects from standard treatments.
Natalizumab has never been used for treating GVHD. It is an experimental drug for this study, because the investigators are investigating a new use for the drug, as a GVHD treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease|
|Actual Study Start Date :||August 2016|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
Experimental: Natalizumab with steroids
For subjects whose GVHD assay is Ann Arbor score 3, the study treatment will consist of two drugs, prednisone (or methylprednisolone) and natalizumab.
Protocol treatment must start within 3 days of the subject's diagnosis of acute GVHD.
Natalizumab 300mg on days 0 and 14.
Other Name: TysabriDrug: steroids
Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
- Complete Response (CR) [ Time Frame: Day 28 ]The primary endpoint for this clinical study is the proportion of complete response, CR (that is, the percent of patients with skin, liver, and GI GVHD - all stage 0) at day 28 of study treatment.
- Overall survival (OS) [ Time Frame: 1 year ]
- Non-Relapse Mortality (NRM) [ Time Frame: 1 year ]Cumulative incidence of Non-Relapse Mortality (NRM)at 6 months and 1 year
- Incidence of treatment-refractory GVHD [ Time Frame: Day 28 ]Cumulative incidence of treatment-refractory GVHD (defined as absence of CR or PR on day 28 of treatment or who receive additional immunosuppression prior to day 28)
- Time to discontinuation of steroid therapy [ Time Frame: Day 28 ]
- Number of additional GVHD therapies [ Time Frame: 1 year ]Number of additional GVHD therapies (defined as the initiation of a new acute GVHD therapy, regardless of duration)
- Number of serious infections [ Time Frame: 6 months ]Number of serious infections (defined as score 3 by the Blood and Marrow Transplant Clinical Trials Network)
- Overall response rate (CR + PR) [ Time Frame: Day 28 ]Overall response rate (CR + PR) at day 28. Partial Response (PR) is defined as improvement in one or more organs involved with GVHD symptoms without progression in others. For a response to be scored as PR on day 28, the patient must be in PR on day 28 and have had no intervening non-study therapy for acute GVHD.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02133924
|Contact: John E Levine, MDfirstname.lastname@example.org|
|Contact: James Ferrara, MDemail@example.com|
|United States, California|
|City of Hope||Recruiting|
|Duarte, California, United States, 91010|
|Contact: Monzr Al Malki, MD 626-256-4673 firstname.lastname@example.org|
|Principal Investigator: Monzr Al Malki, MD|
|United States, Georgia|
|Atlanta, Georgia, United States, 30008|
|Contact: Zaid Al-Kadhimi, MD email@example.com|
|Principal Investigator: Zaid Al-Kadhimi, MD|
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Contact: Clinical Research Office 312-695-1300 firstname.lastname@example.org|
|Principal Investigator: Kehinde Adekola, MD|
|United States, Kansas|
|The University of Kansas Cancer Center||Recruiting|
|Westwood, Kansas, United States, 66205|
|Contact: Kelly Daniels 913-945-6591 email@example.com|
|Principal Investigator: Sunil Abhyankar, MD|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Yi-Bin Chen, MD 617-724-1124 firstname.lastname@example.org|
|Principal Investigator: Yi-Bin Chen, MD|
|United States, Michigan|
|University of Michigan||Withdrawn|
|Ann Arbor, Michigan, United States, 48109|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Anton Mett, MD 507-538-9812 email@example.com|
|Principal Investigator: William Hogan, MB, B Ch|
|United States, New York|
|Mount Sinai Health System||Recruiting|
|New York, New York, United States, 10029|
|Contact: Anne Renteria, MD 212-241-6021 firstname.lastname@example.org|
|Principal Investigator: John Levine, MD|
|New York, New York, United States, 10032|
|Contact 212-305-5098 email@example.com|
|Principal Investigator: Ran Reshef, MD|
|Memorial Sloan Kettering Cancer Center||Not yet recruiting|
|New York, New York, United States, 10065|
|Contact: Doris Ponce, MD 212-639-4838 firstname.lastname@example.org|
|Principal Investigator: Doris Ponce, MD|
|United States, Ohio|
|Ohio State University||Recruiting|
|Columbus, Ohio, United States, 43210|
|Contact: Yvonne Efebera, MD 614-293-5066 email@example.com|
|Principal Investigator: Yvonne Efebera, MD|
|United States, Pennsylvania|
|University of Pennsylvania, Abramson Cancer Center||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: David Porter, MD 215-662-2862 firstname.lastname@example.org|
|Principal Investigator: David Porter, MD|
|United States, Tennessee|
|Nashville, Tennessee, United States, 37232|
|Contact: VICC Clinical Trials Information Office, MD 800-811-8480|
|Principal Investigator: Carrie Kitko, MD|
|Study Chair:||John E Levine, MD||Icahn School of Medicine at Mount Sinai|